MedTrace Logo

Study Evaluating Piperacillin-Tazobactam on Certain Bacteria in Hematology and Oncology Units

NCT00167999 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 200

Last updated 2007-03-15

No results posted yet for this study

Summary

To determine the value of increasing use of piperacillin/tazobactam as empiric therapy and restricting extended-spectrum cephalosporins in reducing the cases of ESBL producing Escherichia coli and Klebsiella pneumoniae in hematology and oncology units

Conditions

  • Gram-Positive Bacterial Infections
  • Escherichia Coli Infections
  • Klebsiella Infections

Interventions

DRUG

piperacillin-tazobactam

Sponsors & Collaborators

  • Wyeth is now a wholly owned subsidiary of Pfizer

    lead INDUSTRY

Principal Investigators

  • Medical Monitor · Wyeth is now a wholly owned subsidiary of Pfizer

Eligibility

Min Age
15 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2005-02-28

Countries

  • South Korea

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00167999 on ClinicalTrials.gov